|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
6 November 2023 |
|
Main ID: |
NCT03144648 |
|
Date of registration:
|
05/05/2017 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women
PRECAMA |
|
Scientific title:
|
Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a Multicenter Population-based Case-control Study |
|
Date of first enrolment:
|
October 12, 2012 |
|
Target sample size:
|
3000 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/ct2/show/NCT03144648 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Brazil
|
Chile
|
Colombia
|
Costa Rica
|
Mexico
| | | |
|
Contacts
|
|
Name:
|
Maria Luisa Garmendia, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
INTA, Universidad de Chile, Santiago, Chile |
|
|
Name:
|
Carolina Porras, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Costa Rica |
|
|
Name:
|
Fabiana Vazquez |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Barretos Cancer Hospital |
|
|
Name:
|
Sabina Rinaldi, PhD |
|
Address:
|
|
|
Telephone:
|
+33 472738485 |
|
Email:
|
rinaldis@iarc.who.int |
|
Affiliation:
|
|
|
|
Name:
|
Gloria I Sánchez, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Grupo Infección y Cáncer, Universidad de Antioquía, Medellín, Colombia |
|
|
Name:
|
Gabriela Torres-Mejía, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Instituto Nacional de Salud Pública, Cuernavaca, Mexico |
|
|
Name:
|
Sabina Rinaldi, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
International Agency for Research on Cancer, Lyon, France |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- woman between 20 and 45 years old
- woman less than 3 years older or younger than the case
- living in the area that the study is taking place during the past 3 years
- woman menstruated at least once in the past 12 months
- woman diagnosed with a primary breast cancer by histopathological examination (only
for cases)
Exclusion Criteria:
- woman receiving tumor treatment, such as radiotherapy, chemotherapy or anti-estrogens
(for example, tamoxifen) (except treatment for non-melanoma skin cancers)
- woman taking (or has previously taken) any of the following medications in the past 6
months: tamoxifen, Evista (raloxifene), Fareston (toremifene), Aromasin (exemestane),
Femara (letrozole), Arimidez (anastrozole) or Megace (megestrol)
- woman suffering from chronic kidney failure
- woman having a pathology that will hinder adequate communication
- woman who is pregnant or nursing
- woman who has been previously diagnosed with a cancer(except for non-melanoma skin
cancers)
- any other reason to exclude
Age minimum:
20 Years
Age maximum:
45 Years
Gender:
Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Breast Cancer Female
|
|
Intervention(s)
|
|
Other: lifestyle
|
|
Primary Outcome(s)
|
|
breast cancer
[Time Frame: at recruitment]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|